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Introduction: Zolpidem is a short acting inducer of sleep and thought to lack benzodiazepine properties such as anxiolysis, anticonvulsion, muscle relaxation and side effects such as dependency. Recently, some cases of Zolpidem abuse and dependency have been reported. In review of literature, we found that the lowest reported dosage of Zolpidem, which caused dependency, was 160 mg daily.
Case Presentation: We reported a 30-year-old unmarried Iranian woman with dysthymic disorder and chronic insomnia treated with 
Zolpidem irregularly. She started to use Zolpidem with 5mg per day irregularly since a year ago but augmented its daily dosage gradually to 100 to 150 mg per day in divided doses. After a period of 16 hours without taking Zolpidem she developed a withdrawal syndrome, with generalized tonic-clonic seizures for two times. She was managed with supportive care and recovered completely.
Conclusions: Zolpidem dependency and withdrawal seizure can occur with a dosage under last reported doses. Therefore, possibility of mentioned problems cannot be excluded at any dosage and physicians should pay more attention to potential of Zolpidem to create these adverse effects.
Keywords:Zolpidem; Dependence; Benzodiazepine
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCom-mercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial us-ages, provided the original work is properly cited.
1. Introduction
Zolpidem (an imidazopyridine derivative agent) is a non-benzodiazepine hypnotic drug with a high affinity to α1 subunit of gamma amino butyric acid-A (GABA-A) receptor and minor anxiolytic and anti-convulsant effects which is indicated for short-term management of insomnia (1). Zol-
pidem is thought to be a safer drug than benzodiazepines (BZD) because of no evidence of abuse or dependence po-tential and a less liability for abuse and dependence (2). Against so many studies indicating no evidence regarding abuse or dependence potential by Zolpidem, case reports of 
Zolpidem abuse or dependence (3-5) and epileptic-seizure related to Zolpidem withdrawal (6-8) are increasing. To our knowledge, most of these case reports have been reported from Western countries (9) and in the Asian population, one case of Zolpidem dependence (10) and one case of Zol-
pidem withdrawal seizure (6) were reported. Nonetheless, in Iranian people, we did not find any similar report. More-over, withdrawal seizure in our case with 100 to 150 mg/day of Zolpidem is the minimum dosage reported up to now.
2. Case PresentationOn October 2013, a 30 year-old unmarried Iranian wom-an (known case of dysthymic disorder) was admitted to Emergency Department (ED) of 22-Bahman Psychiatric Hospital (Qazvin, Iran) with seizure without any history of head trauma. No medications were administered en 
route to the hospital. For about five minutes early after admission, she had seizure one time again, thus she sud-denly had tonic-clonic seizure (full body “shaking” move-ments lasting approximately two minutes) with upward gaze and loss of consciousness. Then, postictal confu-sion with clouded consciousness, regressed attitude and behavior and psycho-motor retardation happened for about two hours. After postictal phase, she indicated to use Zolpidem for a year due to insomnia and not receiving any other medication. She started to use Zolpidem with 5 mg per day irregularly since a year ago but augmented its daily dosage gradually from three months before to 100-150 mg per day in divided doses. She used this dosage for about one month prior to her seizure. She had drug toler-ance, abuse and dependence and if she had not used tab-lets, she would become irritable with decreased energy, feeling of weakness and tremor of hands and feet. In the day of admission, she had not used Zolpidem to maintain her alertness for an important ceremony and after a pe-riod of 16 hours without taking Zolpidem, she developed an abstinence syndrome, with generalized tonic clonic seizures. In her medical history, she did not have any sys-temic, organic, metabolic or endocrine problems unless a history of adenoidectomy 25 years ago and dysthymic disorder from one year ago. She had not experienced any seizure already. In her drug history, she just had used 
Zolpidem with the mentioned dosage. Some of patient's characteristics were summarized in Table 1.
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Table 1.  Some Laboratory and Clinical Results of Patient
Results
Oral temperature, °C 36.8
Heart rate, beats/min 106
Respiratory rate, breaths/min 23
Systolic blood pressure, mmHg 128
Diastolic blood pressure, mmHg 78
Percutaneous O2 saturation, % 99
Serum glucose, mg/dL 112
Her pupils were 4 mm and reactive bilaterally. The initial resting 12 lead electrocardiography (EKG) showed normal sinus rhythm without any abnormal changes. There was no localizing or lateralizing neurological signs. Full blood count, urea, electrolytes, calcium, magnesium, hematol-ogy studies, renal, thyroid and liver function tests had normal results. Substance-drug abuse tests had negative results. Due to the urgency of patient and availability of computed tomography (CT) scan, we first performed spi-ral brain CT scan without contrast, which had normal find-ings. The next day we requested brain magnetic resonance imaging (MRI) and electroencephalography (EEG), which had normal findings. After all evaluations, we did not find any other etiologies except Zolpidem withdrawal. Our pa-tient was detoxified by tapering Zolpidem gradually over one week. We prescribed quetiapine 25 mg before sleep and clonazepam 1 mg per day. No other seizure attack was noted during hospitalization. Finally, after about 10 days hospitalization, she was discharged with a healthy condi-tion with venlafaxine 75 mg thrice daily (t.i.d), clonazepam 1mg daily and quetiapine 25 mg daily at bed time (for her insomnia). In about 6 months follow-up after the first sei-zure, she had no further seizure attacks.
3. DiscussionDuring the last decade, Zolpidem (a non BZD hypnotic drug) was considered a new way for treatment of pa-tients with insomnia as it was suggested that it has the efficacy of BZDs for insomnia but without many side ef-fects. It was suggested that Zolpidem lacked muscle relax-ant, anticonvulsant and anxiolytic properties and poor potential for abuse or dependence (11). GABA-A receptors include α1, α2, α3, α4, and α5 subunits receptors. The α1 sub-unit involves in sleeping mechanisms and α2 subunit contributes to anxiolytic action. BZDs have nonselective affinity to GABA-A subunits (12). Despite the fact, Zolpidem has been suggested to have selective activity on α1 sub-unit, but low affinity for α2, therefore it has minor anxio-lytic action. Our patient reported anxiolysis after using 
Zolpidem. It might be due to effects of this drug in high doses (such as that used by our patient) not only on α1 subunit, but also on other subunits of GABA-A receptors (leading to an anxiolytic effect). In some cases, Zolpidem has been used to achieve euphoria and stimulation and 
not for sedation (3, 13, 14). Since this effect lasted not more than one hour, they repeated the intake in the daytime. A hypothesis about Zolpidem withdrawal is long-term supratherapeutic doses saturation of the lower-affinity α2, α3 and α5 subunits on GABA-A receptors along with α1 subunits (15). Therefore, high-dose Zolpidem may have a paradoxical effect to decrease anxiety, and abrupt dis-continuation of high doses would produce withdrawal symptoms such as anxiety, tremor, palpitation, or seizure (similar to BZDs withdrawal). Withdrawal symptoms of 
Zolpidem were reported in less than 1% of subjects appear-ing within 48 hours of discontinuation (16). One of the probable factors associated with adverse effects of Zolpi-
dem is gender. Women have been found to have a signifi-cantly higher serum Zolpidem concentration than men at equivalent dosage (17). Some studies demonstrated that sudden discontinuation of Zolpidem by doses within the normal recommended range 2 to 4 weeks after treatment has not been associated with withdrawal symptoms (2, 18). Zolpidem dependence and withdrawal symptoms have been reported in patients with doses between 160 to 2000 mg per day (7, 10). Therefore, to our knowledge, withdrawal seizure in our case with the mentioned dos-age of Zolpidem is the minimum dose reported up to now. According to other case reports and studies and our case, 
Zolpidem, soon after sudden discontinuation, causes withdrawal symptoms including insomnia, anxiety and epileptic attack, especially at high doses and long-term use. Concerns about Zolpidem abuse, dependence and withdrawal seizure are increasing in the recent years due to increased number of reported cases. Maybe, this event is due to unawareness of many physicians and patients about the potential of Zolpidem to create these problems. In addition, use of this drug out of its therapeutic goals and short half-life predisposes adverse events. Our case suggested that Zolpidem can potentially lead to depen-dence and withdrawal seizure in Iranian population, also can occur with a dosage under last reported doses. Besides, the possibility of mentioned problems cannot be excluded at any dosage. We suggest physicians to pay more attention to the potential of Zolpidem to create de-pendence and withdrawal seizure. Besides, they should always keep its effects in their mind and subtilize during prescription of Zolpidem for any patients and at any dos-es, especially for those with a previous history of drug or substance abuse and at high doses. This study presented a new dosage of Zolpidem that causes withdrawal seizure. However, this is a case study and it needs further studies to conclude about adverse effects of Zolpidem.
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